D i s c l a i m e r : T h e m a n u s c r i p t a n d i t s c o n t e n t s a r e c o n f i d e n t i a l , i n t e n d e d f o r j o u r n a l r e v i e w p u r p o s e s o n l y , a n d n o t t o b e f u r t h e r d i s c l o s e d .

The investigation of sudden death is one of the few enduring responsibilities of the Coronial system that had its origins in 11 th century Britain and was formally established by the articles of Eyre in 1194. 1 Persons finding a body from a sudden or unnatural death were required to raise the "hue and cry" and to notify the coroner.
Although the familial nature of sudden death, including from structural and electrical cardiomyopathies, has been recognized for many decades or more, British pathologist MJ Behr and colleagues 4 clinically evaluated 147 first-degree relatives of 32 sudden arrhythmia death syndrome (SADS) victims with a 22% diagnostic yield for the cause of SCD, whereas more recently, in a larger cohort of victims, a 13.5% yield was identified. 5 Recent studies of the molecular autopsy approach using gene panels of varying sizes [6] [7] [8] or whole exome sequencing 9 have identified varying diagnostic yields averaging of 13%. Large studies using a combined approach of family assessment combined with molecular diagnosis of decedent and/or family members provided larger diagnostic yields than family or molecular assessment alone, with an averaged combined diagnostic yield of 31%.
In the current study,
channelopathy and cardiomyopathy genes in a sudden unexpected death cohort of 296 decedents, applying a statistical framework to filter candidate causal variants based on factors that include prevalence and penetrance of the diseases related to those variants 18 and reporting the results according to the recent ACMG framework. 19 Using these stringent guidelines, they identified 17 pathogenic or likely pathogenic (P/LP) variants in 16 subjects, or 5.4% of their cohort.
However, the authors also identify 46 novel variants, and 130 variants with allele counts lower than that expected on the basis of their related disease. This finding demonstrates the high stringency of ACMG guidelines, for which novelty or rarity represent only a single moderate criterion for pathogenicity. In the absence of family data (identifying a de novo or segregating status for the variant) or a well-established functional assay, such variants will not fulfill P/LP status.
A specific comparison to the recent study of Lahrouchie and colleagues 11 is warranted, as that study also applied ACMG criteria. Lin et al. 17 used GNOMAD instead of EXAC and this may have given rise to different minor allele frequencies that may have altered yield in the Lahrouchi paper. There is lack of data on frequent rare variants or disease associated variants in non-Caucasian ethnic groups. The Lahrouchi study was predominantly white Caucasian compared to 50% African American in the current study. The lack of available family data limited the ability to upgrade VUSs to P/LP. This was helpful with supporting pathogenicity for a number of novel variants using family segregation or confirmation of de novo variants in the Lahrouchie paper.
In parallel with sudden cardiac death investigation, a system for investigation of diagnostic yield than SCD victims, 14 as the proband demonstrating the clearest disease penetrance is thus available for both detailed clinical and genetic assessment. In the assessment of such cardiac arrest survivors, clinical assessment again appears to provide a higher diagnostic yield 15 than genetic assessment alone. 16 The authors are somewhat unique as a large medical examiner's office performing their own sequencing and variant interpretation, as opposed to most coroner/M.E. systems that use commercial labs for this work. While part of the rationale for this is the wide variation of reporting from commercial laboratories, representatives from such labs did contribute to ACMG guidelines and most are now using the ACMG framework for reporting. It seems infeasible for small to moderate Coroner/ME programs to reproduce the described system. It would be of interest to know how the variant identification and interpretation process reported compares to that within heritable heart disease clinics in the New York City region, and whether hospital 
